Oncobiologics Inc (NYSE:ONS) shares fell 10.9% during mid-day trading on Monday . The company traded as low as $1.65 and last traded at $1.80. 1,462,017 shares were traded during mid-day trading, an increase of 802% from the average session volume of 162,038 shares. The stock had previously closed at $2.02.

Separately, Zacks Investment Research raised Oncobiologics from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Saturday, June 10th.

The company’s market cap is $43.68 million. The stock’s 50-day moving average price is $1.80 and its 200-day moving average price is $2.98.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/13/oncobiologics-inc-ons-trading-down-10-9.html.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

Receive News & Stock Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related stocks with our FREE daily email newsletter.